Significats de chimeric antigen en anglès

Neurotoxicity is an important and common complication of chimeric antigen receptor-T cell therapies.

This chimeric antigen may be used as research and developed into HIV diagnostic reagents.

One form of immunotherapy uses chimeric antigen receptors (CAR) to target tumor-associated antigens.

Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials.

The modified cells, called chimeric antigen receptor T-cells, or CAR-T, are then infused into the patient.

Purpose: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR).

Expanded NK cells can be transduced with genes encoding chimeric antigen receptors that stimulate tumor cell-specific cytotoxicity.

It is unknown if human chimeric antigen receptor (CAR)-expressing T cells can also undergo memory polarization.

Background: Tumors can be targeted by the adoptive transfer of chimeric antigen receptor (CAR) redirected T-cells.

We generated a second generation CD33-specific chimeric antigen receptor capable of redirecting cytolytic effector T cells against leukemic cells.

As a proof of concept, engineered chimeric antigen receptor T cells targeting CEACAM5 induced antigen-specific cytotoxicity in NEPC cell lines.

Using plant-virus transient expression to produce this unique chimeric antigen will facilitate the development and production of an experimental HCV vaccine.

Neurotoxicity is associated with cytokine release syndrome, which occurs in the setting of in-vivo chimeric antigen receptor-T cell activation and proliferation.

Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing.

Adoptive T-cell therapy with anti-CD19 chimeric antigen receptor (CAR)-expressing T cells is a new approach for treating advanced B-cell malignancies.

The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells.